Li Z, Zhuang X, Pan C-H, Yan Y, Thummalapalli R, Hallin J, Torborg S, Singhal A, Chang JC, Manchado E et al..  2024.  Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.. Cancer Discov. 14(2):308-325.

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GHo, Walch H, Aveson VG, Falvo DJ et al..  2024.  Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.. Cancer Cell. 42(9):1614-1629.e5.

Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, O'Reilly EM, Park W, Chandwani R, Wei A et al..  2024.  KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers.. JCO Precis Oncol. 8:e2400263.

Xue Y, Lito P.  2017.  Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.. Clin Cancer Res. 23(6):1365-1367.

Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW.  2015.  Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.. Cell. 161(7):1539-1552.

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S et al..  2013.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.. Mol Cell. 50(2):185-99.